Want to create an interactive transcript for this episode?
Podcast: CME
Episode: RAS Across Tumors: Who to Test When
Description:
Faculty: Kathryn Arbour
Faculty: Eileen M. O'Reilly, MD
This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.